FREE PREVIEW
Peptides and Healthy Aging
Read mitochondrial, biomarker and longevity claims in context.
AI-assisted editorial edition · Independent clinical review pending.
Before you read
This selected-source guide explains research for education. It is not a diagnosis, prescription or personal treatment plan. Do not start, stop or change medicines, combine products, or delay care because of this guide. Discuss proposed uses and interactions with a qualified clinician and pharmacist. It does not establish a clinician-patient relationship.
What this edition can and cannot answer
A selected-source guide to what the available human, animal and cell records can and cannot answer; no therapeutic ranking, dose schedule or claim of proven longevity benefit.
- A change in ATP production, circulating peptide concentration or telomere length does not establish longer life, preserved independence or a useful treatment effect.
- MOTS-c biomarker studies are not administration trials. Disease-specific elamipretide results cannot be generalized to healthy consumers. Epitalon, epithalamin and pineal extracts require separate identities.
- Bounded source closure checked 27 October 2026 using the named full reports, publisher/PubMed records and available companion documents. This is not a systematic literature search or exhaustive integrity review. Protocol comparisons and specified access, overlap and translation checks remain unfinished.
- AI-assisted editorial draft. Human editorial, qualified independent clinical, legal, reader-test and accessibility reviews are pending. Purchases and PDF downloads are not yet available.
SECTION 01
Peptides and Healthy Aging
A claim about “cellular energy” or “younger biological age” can sound like a claim about living better for longer. This guide helps you identify which outcome was actually tested, compare the selected findings and prepare questions that preserve their limits.
Contents
SECTION 02
Start with the outcome you care about
Write down a concrete reader outcome before looking at the molecule: maintaining daily function, reducing fatigue, preventing disease or living longer. Then compare it with the reported measurement. A laboratory or physiological signal may be worth studying without answering that reader outcome.
| Selected example | What the record measures | Decisive limit |
|---|---|---|
| Elamipretide in selected older adults [1] | Muscle mitochondrial energetic capacity after a single infusion | Short-term surrogate; selected population |
| Elamipretide in mitochondrial myopathy [2][3] | Walking distance and symptom scales | Disease-specific treatment question |
| MOTS-c after exercise [4] | Circulating peptide concentrations | Exercise was assigned; peptide was not |
| Epitalon in cell lines [5] | Telomere and pathway measurements | Cells are not human longevity outcomes |
These are four different evidence questions. This guide does not combine them into an “anti-aging score”. It also does not treat a larger bibliography or an appealing mechanism as stronger clinical evidence.
Examples and source locations: [1][2][3][4][5]. Complete Q01-Q15 source appraisal, study-family reconciliation and independent clinical review remain pending.
SECTION 03
Sources, review gaps and edition
These selected educational examples are not a systematic review. Existing PDFs were identity/hash checked and inspected as full reports; the two pineal-preparation papers now have separate bibliographic identities. The 2004 paper remains abstract-only.
The cited papers have not completed independent review. Remaining actions include protocol and supplement comparison, study-family overlap, exact corrected-figure checks, the MMPOWER-3 fatigue discrepancy, the MOTS-c group wording discrepancy, full text for the 2004 pineal report, and qualified review of any consequential translated claim.
Report a source or edition correction · Educational-use policy
FOLLOW THE EVIDENCE
Sources and reading limits
In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial
Human surrogate example; appraisal pending.
Results p1; Methods p4; printed abstract p1.
A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy
Disease-specific crossover trial; appraisal pending.
Abstract/Results p1; trial design p2; endpoint procedures p3.
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy The MMPOWER-3 Randomized Clinical Trial
Disease-specific trial; appraisal pending.
Methods/printed abstract p1; primary Results p2.
Effect of aerobic and resistance exercise on the mitochondrial peptide MOTS-c in Hispanic and Non-Hispanic White breast cancer survivors
Human biomarker example; no MOTS-c treatment effect.
Printed abstract/results p1; exercise was assigned.
Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity
Cell-line mechanism; corrected figure version; no clinical risk/benefit estimate.
Full report, Methods and Results; corrected Figures 1–3; see correction [7].
FDA: Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks
United States compounding context; not global legal status.
MOTS-c entry; checked 27 October 2026.
Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity (2025; issue 2026)
Integrity notice; use corrected figures and preserve cell-model limits.
Publisher correction, published 15 November 2025: Figures 1, 2 and 3 were incorrect and were replaced; original article corrected. Current publisher PDF matches the existing local PDF hash.
Korkushko et al. Geroprotective effect of epithalamine (pineal gland peptide preparation) in elderly subjects with accelerated aging (2006)
Small disease-specific human report; pineal extract, not synthetic Epitalon.
PMID 17426848; Bulletin of Experimental Biology and Medicine 142:356–359. Author-posted scan visually inspected, printed pp356–359 (PDF pp2–5).
Korkushko et al. Effect of peptide preparation epithalamin on circadian rhythm of epiphyseal melatonin-producing function in elderly people (2004)
Human melatonin-rhythm abstract; methods/harms access gap.
PMID 15452611; PubMed abstract and publisher preview checked 27 October 2026; full report not acquired.
Edition and corrections
Web reading edition: 4 November 2026. Manuscript prepared: 2026-10-27. This web-format update does not represent a new literature search or completed clinical review.
Edition: PA-GUIDE-HEALTHY-AGING-2026-10-27-0.2-REVIEW-DRAFT
Scientific interpretation, source-access limits and independent review are separate from publication of this reading view.
Report a correction →